MIRM vs ELDN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MIRM Captures Institutional Edge (2โ2 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Mirum Pharmaceuticals, Inc. Common Stock (MIRM) driven by superior Momentum & Technical, Options & Structure while ELDN counters with relative strength in Valuation, Growth & Margin. Fundamentally, MIRM trades at N/M Forward P/E with -21.6% operating margin (+39.6% YoY revenue) versus ELDN at 5.4x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, MIRM sits in CONSOLIDATION (15th %ile IV; Dealer Gamma Walls on Pro) against ELDN sits in BREAKDOWN (28th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MIRM | ELDN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $6.2B | $160.5M | Larger Scale | MIRM |
| Trailing P/E Ratio Valuation | N/M | 5.4x | Lower Multiple | ELDN |
| Forward P/E Ratio Valuation | N/M | 5.4x | Lower Multiple | ELDN |
| Revenue Growth (YoY) Growth | +39.6% | +0.0% | Higher Growth | MIRM |
| Operating Margin (TTM) Profitability | -21.6% | 0.0% | Higher Margin | ELDN |
| Net Profit Margin Profitability | -134.8% | 0.0% | Higher Margin | ELDN |
| Return on Equity (ROE) Capital Efficiency | -760.0% | -105.7% | Higher ROE | ELDN |
| 52-Week Range Position Momentum | 49% ($63โ$130) | 14% ($1โ$4) | Stronger Trend | MIRM |
| Beta / 30D Volatility Risk Regime | 0.86ฮฒ ยท 48% Vol | 1.78ฮฒ ยท 116% Vol | Lower Realized Risk | MIRM |
| Unified Institutional Score Composite Signal | 51.1 / 100 (HOLD) | 44.3 / 100 (HOLD) | Higher Composite | MIRM |